CD22 is a transmembrane glycoprotein with a relative molecular mass of 135kDa . It has two types: α and β . It is specifically expressed in B cells and its expression is up-regulated in activated B cells. Human CD22 has a full length of 827 amino acids, including the extracellular segment ( 668 amino acids), the transmembrane region ( 19 amino acids) and the intracellular region ( 140 amino acids). CD22 is a member of the B cell inhibitory receptor family and one of the co-receptors on the surface of B cells. CD22 forms a loose complex with the B cell receptor through the lectin-like domain in the extracellular zone. After cross-linking with BCR , it initiates an intracellular signal cascade, thereby modulating the BCR- mediated signal transduction pathway and the function of B cells. To CD22 as a target CAR-T it has been used to treat B lymphocyte tumors. This product is a CD22-FC recombinant protein (the FC tag can be removed by enterokinase), which can be used for monoclonal antibody screening or antibody function verification.

Product name: Recombinant human CD22 protein

Species: Human origin

Gene sequence number: P20273

Tags: Human-Fc Tag

Tag site: N- terminal

Restriction site: enterokinase

Expression area: extracellular segment ( 20-687AA )

Host cell: 293F

Purity: ＞90%

Purification method: Protein A column

Preservation system: PBS+20% glycerol

Storage conditions: -80℃

Illustration: Lane M on the left is the protein MW marker, Lane 1 is 15ug CD22-Fc protein;

The right image shows the FACS detection of CD22 protein binding to 293T overexpressing anti-CD22-CAR.

Reference materials:

1. CD22 is a negative regulator of B-cell receptor signalling

2. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP

3.CD22 regulates thymus-independent responses and the lifespan of B cells